The VA recommends against offering this agent to patients with Alzheimer’s dementia, mild or otherwise.
Formulary Watch
Latest News
All News
Advertisement
The program and proposed integrations could produce $15 million in savings annually.
The decision follows an advisory committee recommendation not to approve because of safety issues.
Libtayo also reduced the risk of death by 29% compared with chemotherapy alone.
A decision on the plaque psoriasis therapy is expected in the second quarter of 2022.
The graft-versus-host disease therapy has also been added to NCCN Guidelines.
Previously patients administered as two, 75-mg shots. Now they can inject a single 150-mg dose.
The bottles have a counterfeit foil seal or label and contain an incorrect number of tablets.
Current drug shortages based on FDA data, prepared by Formulary Watch.
The therapy for HIV-related pneumonia was exposed to cold weather during shipment.
Advertisement
The therapy can now be used for post-exposure prevention in people at high risk for progression to severe disease.
The PDUFA date has been set for December 4, 2021; FDA has designated this as a Priority Review.
The PDUFA date for this indication is December 4, 2021.
A single application targets the infection without entering the circulatory system.
The FDA is expected to make a decision on this indication by December 1, 2021.
The therapy had received accelerated approval in 2011 but a phase 3 confirmatory trial found it did not meet the end point of progression-free survival.
The sickle cell disease therapy will now be on the Preferred Drug List.
This is the first new approval for lupus in a decade.
The agent targets excessive daytime sleepiness.
Pharmacies will need to obtain pre-dispense authorization for clozapine.
Some fatal cases of ketoacidosis have occurred, and high-risk patients should be monitored when starting treatment.
The FDA is requesting an additional study to demonstrate tenapanor lowers serum phosphorus.
Drugs that provide only incremental benefit may not be included on clinical pathways.
The approval allows for substitution at the pharmacy counter for Lantus, its reference product.
The agency has stopped enrollment in all ongoing trials.
The findings were similar in people with or without diabetes.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Tubeless AID Systems Boost HRQoL in Type 1 Diabetes
2
Sonye Danoff, M.D., Ph.D., Discusses the FIBRONEER Study for IPF
3
Current Guideline Definitions of Barrett’s Esophagus May Fall Short in Detecting Esophageal Cancers
4
U.S. Lung Cancer Survival Improves to Nearly 30%, but Funding Cuts Threaten Progress
5
